These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 25451849)

  • 21. Influence of laropiprant, a selective prostaglandin D2 receptor 1 antagonist, on the pharmacokinetics and pharmacodynamics of warfarin.
    Schwartz JI; Liu F; Stroh M; Gipson A; Johnson-Levonas AO; Lasseter KC; Lai E; Wagner JA
    Am J Ther; 2009; 16(3):215-23. PubMed ID: 19454860
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Hereditary warfarin resistance].
    Lappegård KT
    Tidsskr Nor Laegeforen; 2000 Nov; 120(27):3257-8. PubMed ID: 11187165
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of rivaroxaban to the international normalized ratio when switching to warfarin for anticoagulation as determined by simulation studies.
    Siegmund HU; Burghaus R; Kubitza D; Coboeken K
    Br J Clin Pharmacol; 2015 Jun; 79(6):959-66. PubMed ID: 25510952
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of Drug-Drug Interaction between Warfarin and Aprepitant and Its Effects on PT-INR of Patients Receiving Anticancer Chemotherapy.
    Takaki J; Ohno Y; Yamada M; Yamaguchi R; Hisaka A; Suzuki H
    Biol Pharm Bull; 2016 May; 39(5):863-8. PubMed ID: 26948084
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effects of changing the timing of warfarin administration in combination with fluconazole on prolongation of the PT-INR: a case report.
    Akamatsu H; Nakagawa H; Matsumaru I; Hashizume J; Harasawa H; Kodama Y; Miura T; Ohyama K
    J Pharm Health Care Sci; 2023 Apr; 9(1):11. PubMed ID: 37004089
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Elevated international normalized ratio values associated with concomitant use of warfarin and ceftriaxone.
    Clark TR; Burns S
    Am J Health Syst Pharm; 2011 Sep; 68(17):1603-5. PubMed ID: 21856805
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Prediction of the international normalized ratio and maintenance dose during the initiation of warfarin therapy.
    Vadher B; Patterson DL; Leaning M
    Br J Clin Pharmacol; 1999 Jul; 48(1):63-70. PubMed ID: 10383562
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.
    Jiang X; Williams KM; Liauw WS; Ammit AJ; Roufogalis BD; Duke CC; Day RO; McLachlan AJ
    Br J Clin Pharmacol; 2005 Apr; 59(4):425-32. PubMed ID: 15801937
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A randomized controlled trial of empiric warfarin dose reduction with the initiation of doxycycline therapy.
    Dowd MB; Kippes KA; Witt DM; Delate T; Martinez K
    Thromb Res; 2012 Aug; 130(2):152-6. PubMed ID: 22221937
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Possible interaction between warfarin and fluconazole.
    Gericke KR
    Pharmacotherapy; 1993; 13(5):508-9. PubMed ID: 8247921
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Enhanced anticoagulant effect of warfarin in a patient treated with cloxacillin.
    Marusic S; Gojo-Tomic N; Bacic-Vrca V; Franic M
    Int J Clin Pharmacol Ther; 2012 Jun; 50(6):431-3. PubMed ID: 22677303
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Warfarin monitoring with viscoelastic haemostatic assays, thrombin generation, coagulation factors and correlations to Owren and Quick prothrombin time.
    Nilsson CU; Strandberg K; Reinstrup P
    Scand J Clin Lab Invest; 2018 Sep; 78(5):358-364. PubMed ID: 29792060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of fimasartan, an angiotensin receptor type 1 blocker, on the pharmacokinetics and pharmacodynamics of warfarin in healthy Korean male volunteers: a one-sequence, two-period crossover clinical trial.
    Gu N; Kim BH; Lim KS; Kim SE; Nam WS; Yoon SH; Cho JY; Shin SG; Jang IJ; Yu KS
    Clin Ther; 2012 Jul; 34(7):1592-600. PubMed ID: 22727611
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The effect of rofecoxib on the pharmacodynamics and pharmcokinetics of warfarin.
    Schwartz JI; Bugianesi KJ; Ebel DL; De Smet M; Haesen R; Larson PJ; Ko A; Verbesselt R; Hunt TL; Lins R; Lens S; Porras AG; Dieck J; Keymeulen B; Gertz BJ
    Clin Pharmacol Ther; 2000 Dec; 68(6):626-36. PubMed ID: 11180023
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Interaction between warfarin and trazodone.
    Small NL; Giamonna KA
    Ann Pharmacother; 2000 Jun; 34(6):734-6. PubMed ID: 10860134
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and pharmacodynamic re-evaluation of a genetic-guided warfarin trial.
    Zambon CF; Pengo V; Moz S; Bozzato D; Fogar P; Padoan A; Plebani M; Groppa F; De Rosa G; Padrini R
    Eur J Clin Pharmacol; 2018 May; 74(5):571-582. PubMed ID: 29396738
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of pitavastatin vs. rosuvastatin on international normalized ratio in healthy volunteers on steady-state warfarin.
    Yu CY; Campbell SE; Zhu B; Knadler MP; Small DS; Sponseller CA; Hunt TL; Morgan RE
    Curr Med Res Opin; 2012 Feb; 28(2):187-94. PubMed ID: 22149769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effect of eslicarbazepine acetate on the steady-state pharmacokinetics and pharmacodynamics of warfarin in healthy subjects during a three-stage, open-label, multiple-dose, single-period study.
    Vaz-da-Silva M; Almeida L; Falcão A; Soares E; Maia J; Nunes T; Soares-da-Silva P
    Clin Ther; 2010 Jan; 32(1):179-92. PubMed ID: 20171423
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of montelukast on the pharmacokinetics and pharmacodynamics of warfarin in healthy volunteers.
    Van Hecken A; Depré M; Verbesselt R; Wynants K; De Lepeleire I; Arnout J; Wong PH; Freeman A; Holland S; Gertz B; De Schepper PJ
    J Clin Pharmacol; 1999 May; 39(5):495-500. PubMed ID: 10234597
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lack of effect of lacosamide on the pharmacokinetic and pharmacodynamic profiles of warfarin.
    Stockis A; van Lier JJ; Cawello W; Kumke T; Eckhardt K
    Epilepsia; 2013 Jul; 54(7):1161-6. PubMed ID: 23614393
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.